Results 21 to 30 of about 1,261,156 (366)

Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system

Scientific Reports
Tafamidis is the world's first and only oral drug approved to treat the rare disease transthyretin amyloid cardiomyopathy (ATTR-CM). Medicines are known to have different adverse reactions during the course of treatment.
Fan Wu, He Zhu, Yue Zhang
doaj   +3 more sources

Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system [PDF]

Scientific Reports
Neuropsychiatric adverse events (AEs) significantly impact the quality of life of patients using avapritinib. However, the majority of current data comes from pre-marketing, with limited real-world studies.
Wei Mao, Junyan Jiang, Yanping Xia, Lin Zhang   +3 more
doaj   +2 more sources

Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS) [PDF]

Scientific Reports
Progestogens commonly used in the clinic include levonorgestrel, etonogestrel, medroxyprogesterone, hydroxyprogesterone, progesterone, desogestrel, and megestrol.
Hui Gao, Xiaohan Zhai, Yan Hu, Hang Wu
doaj   +2 more sources

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database

Frontiers in Pharmacology, 2023
Mepolizumab is primarily used in the treatment of asthma, eosinophilic granulomatosis with polyangiitis, eosinophilia syndrome, and chronic rhinitis with nasal polyps.
Fan Zou, Chengyu Zhu, Siyu Lou, Zhiwei Cui, Dan Wang, Yingyong Ou, Li Wang, Junyou Chen, Yuanbo Lan   +8 more
semanticscholar   +1 more source

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system

Frontiers in Immunology, 2023
Background Risankizumab, a humanized IgG1 monoclonal antibody that selectively inhibits IL-23, is currently approved for the treatment of moderate-to-severe plaque psoriasis and Crohn’s disease.
Yamin Shu, J. Chen, Yiling Ding, Qilin Zhang   +3 more
semanticscholar   +1 more source

Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database

Frontiers in Endocrinology, 2022
Objective Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have significantly improved clinical effects on glycemic control. However, real-world data concerning the difference in gastrointestinal adverse events (AEs) among different GLP-1 RAs are ...
Lu Liu, Jia Chen, Lei Wang, C. Chen, Li Chen   +4 more
semanticscholar   +1 more source

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system

CNS Neuroscience & Therapeutics, 2023
Objective Quetiapine, an atypical second‐generation antipsychotic drug, is approved for treatment of schizophrenia, bipolar disorder, and depression. Due to the limitations of clinical trials, the association between quetiapine and rare cardiac adverse ...
Yamin Shu, Yiling Ding, Lulu Liu, Qilin Zhang   +3 more
semanticscholar   +1 more source

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System

Frontiers in Pharmacology, 2022
Purpose: Secukinumab was approved for the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, the long-term safety of secukinumab in large sample population was unknown.
Yamin Shu, Yufeng Ding, Yanxin Liu, Pan Wu, Xucheng He, Qilin Zhang   +5 more
semanticscholar   +1 more source

A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System

Clinical Epidemiology, 2022
Background Olaparib, the world’s first poly ADP-ribose polymerase (PARP) inhibitor (PARPi), has been approved for treatment of ovarian cancer, breast cancer, pancreatic cancer and prostate cancer by FDA.
Yamin Shu, Xucheng He, Yanxin Liu, Pan Wu, Qilin Zhang   +4 more
semanticscholar   +1 more source

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib

Scientific Reports, 2022
Niraparib was approved for the treatment of platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube and primary peritoneal cancer. The authors retrospectively investigated niraparib-related adverse events (AEs) through data mining of the ...
Menglin Guo, Yamin Shu, Guosong Chen, Juan Li, Fei Li   +4 more
semanticscholar   +1 more source